Search PubMed⌕ Search

Biomedical subjects

S Todo

Publications and source records attributed to S Todo.

At least 577 records · Page 32Linked to original sources
PubMed1987

Analysis of donor criteria for the prediction of outcome in clinical liver transplantation.

The results of 219 orthotopic human liver transplants performed during 1985 at the University of Pittsburgh were reviewed to determine whether donor parameters could be used to predict the quality of early graft function. Multivariate discriminant analysis demonstrated that traditional parameters of donor assessment are unreliable predictors of poor graft function. Furthermore, 56% of the donors considered poor by conservative selection criteria produced livers with good early posttransplant function. Survival of recipients of primary allografts from donors rated poor was no different than survival of recipients of allografts from donors rated good.

Adolescent↗
PubMed1987

OKT3 in the reversal of acute hepatic allograft rejection.

OKT3 was an effective immunosuppressant agent in patients with acute cell-mediated allograft rejection that had not responded to initial steroid therapy. OKT3 was also valuable for treating patients with early hepatic graft dysfunction caused by other factors than rejection. In such recipients, the doses of CyA can be greatly reduced, allowing recovery of frequently damaged kidneys while maintaining effective immunosuppression.

Adolescent↗
PubMed1987

The Denver-Pittsburgh liver transplant series.

Liver transplantation is now the preferred treatment for many diseases leading to end-stage liver disease. Transplantation for cancer has been disappointing and there is a significant recurrence rate after transplantation in hepatitis B-virus carriers. Additional strategies will have to be developed if we are to improve the results of transplantation for these patients. The role of immunological factors in liver transplantation continues to reveal significant differences from their role in renal transplantation and will continue to be an interesting area of study for years to come.

Adolescent↗
PubMed1987

Pediatric liver transplantation.

Liver transplantation, which once was an experimental procedure of no practical interest, has become the preferred treatment for infants and children dying of almost all non-neoplastic end-stage liver diseases. Liver replacement is being provided by many well-trained teams on all of the continents, as is evident from the program today--the first international symposium on pediatric liver transplantation. I have been honored in giving the first paper in the process of introducing the remarkable work of a gifted younger generation of physicians and surgeons.

Cyclosporins↗
PubMed1987

Hypercalcemia in a case of childhood acute lymphoblastic leukemia.

Severe hypercalcemia (serum calcium, 4.25-5.25 mmol/l), in association with osteolytic bone lesions, was found in a girl aged 2 yr 7 mo with common acute lymphoblastic leukemia (ALL). Hormonal studies excluded the possibility of the hypercalcemia being caused by primary hyperparathyroidism or ectopic parathyroid hormone secretion. Increased plasma prostaglandin E2 (PGE2) levels (130 ng/l), probably produced by leukemic cells, were considered to be one of the pathogenic mechanisms responsible for the occurrence of hypercalcemia in this patient. Both the hypercalcemia and the abnormal plasma PGE2 level returned to normal after chemotherapy.

Calcium↗
PubMed1987

Clinical considerations in orthotopic liver transplantation.

Progress in immunosuppression, surgical techniques, and perioperative care has promoted orthotopic liver transplantation from an experimental procedure to an accepted clinical treatment. Orthotopic liver transplantation, in turn, has changed the treatment of terminal liver disease from care that is largely treatment of symptoms and support to cure, but at the price of major surgery and life-long immunosuppression. This article reviews the current status of liver transplantation as practiced at the University of Pittsburgh.

Graft Rejection↗
PubMed1987

[Therapeutic effect of adjuvant combination chemotherapy in the treatment of 8 cases of childhood soft-tissue sarcoma].

The therapeutic results obtained in eight cases of childhood malignant soft-tissue sarcoma are summarized. Male to female ratio was 4:4, four were rhabdomyosarcoma and 5 were defined as Group I/II. Adjuvant combination chemotherapy was administered soon after biopsy (3 cases), or after partial or total resection (3 cases) of the primary tumor. In one case, irradiation was employed and in the remaining case, no further therapy was given after surgery. The three patients who underwent total removal of the tumor followed by adjuvant chemotherapy including adriamycin, and a patient with a partially resected intra-orbital tumor which responded well to a similar form of chemotherapy are currently alive after 26+ to 71+ months. By contrast, four patients whose tumors were too bulky to be resected responded poorly to chemotherapy and died. It must be emphasized that adjuvant chemotherapy is of limited value in the treatment of advanced childhood soft-tissue sarcoma.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1987

[Therapeutic results in 22 cases of childhood non-Hodgkin's lymphoma treated by ACOP combination chemotherapy].

Twenty-two cases of childhood non-Hodgkin's lymphoma were treated during the past 8 years from 1979 to 1986. Median age was 7 years 4 months and the age range was from 2 years 4 months to 14 years 9 months, the male to female ratio being 18 : 4. Primary sites were common in the mediastinum (n = 7) and abdomen (n = 6) followed by submandibular lymph nodes (n = 3). According to Murphy's staging system, 7 were in stage I/II and 15 in stage III/IV. Histological studies of lymphoma tissues and blasts in the cerebrospinal fluid, pleural effusion or ascites revealed that 9 cases were lymphoblastic lymphoma while only 3 were defined as Burkitt's lymphoma. With our protocol of systemic combination chemotherapy (i.e. ACOP), intrathecal methotrexate and/or involved field irradiation, twenty-one out of the 22 cases (93%) attained complete remission and 14 patients are currently alive in continuous complete remission, with a median survival of 28+ months (range 6+ approximately 76+ months).

Adolescent↗
PubMed1987

[Clinical features and therapeutic results in 14 cases of malignant histiocytosis in childhood].

Fourteen children, 4 males and 10 females, with malignant histiocytosis (MH) were treated between July 1980 and June 1986. None of them had an affected sibling with a similar disorder. Septic-type fever was the most prominent symptom in all cases. Hepatosplenomegaly was present in 13 cases, lymphadenopathy, skin rash and jaundice in 8, pulmonary infiltration or pleural effusion on chest X-ray in 8, convulsion in 6, and renal involvement in 5 out of the 14 cases. Disseminated intravascular coagulation (DIC) was seen in 13 cases and this occurred within two weeks from onset in 6 cases. Pancytopenia, abnormal results of liver function tests, hypofibrinogenemia and hypocholesterolemia were common. The diagnosis was made for all 14 cases by characteristic clinical symptoms, signs, and bone marrow findings. In 8 cases, biopsy or autopsy specimens confirmed the diagnosis. Two patients died prior to chemotherapy. Twelve patients were treated with adriamycin, cyclophosphamide, vincristine and prednisone (ACOP). Complete response (CR) was achieved in five patients, and another two patients attained CR after subsequent treatment with other combinations including VP 16-213. These 7 complete responders are now alive and free of disease 11+ to 70+ months (median, 50+ months) from the onset of disease. All partial and non-responders died within 6 months with a median survival of 20 days. Among several clinical features as prognostic indicators, renal involvement, convulsion, and DIC occurring within 2 weeks were significantly related to poor outcome. Although MH is an aggressive disease with a poor prognosis, prompt diagnosis and early treatment with intensive systemic combination chemotherapy should further improve the outcome.

Adolescent↗
PubMed1987

[Treatment of a case of childhood acute non-lymphocytic leukemia (ANLL) using high-dose cytosine arabinoside for intensification of early therapy].

A 12-year-old girl with acute non-lymphocytic leukemia was treated with a protocol involving high-dose cytosine arabinoside (Ara-C) for intensification of early therapy. The patient, who had been revealed to have CNS infiltration on admission, achieved complete remission after receiving ACMA/BHAC combination and intrathecal MTX. As an early intensification treatment, ID/HD Ara-C was safely and effectively administered; this consisted of ADR (45 mg/m2 iv) Day 1, intermediate-dose Ara-C (0.5 g/m2, 1-h drip, q. 12 h) Days 2-4, and high-dose Ara-C (3 g/m2, 3-h drip, q. 12 h) Days 10-11, followed by L-asp (6,000 U/m2, im) on Day 12. Ten months later, the patient has been in continuous complete remission. High-dose Ara-C should be included with caution as an early intensification of treatment to improve the therapeutic results of childhood ANLL.

Aclarubicin↗
PubMed1986

Cycloheximide reduces PGD2 or delta 12-PGJ2 cytotoxicity on NCG cells.

To study the precise mechanism of cytotoxic activity of PGD2 or delta 12-PGJ2 (a biologically active metabolite of PGD2), we examined the effect of various compounds on PGD2 or delta 12-PGJ2 cytotoxicity, using a human neuroblastoma cell line (NCG). Cycloheximide (CHM) specifically protected PGD2 cytotoxicity on NCG cells. When delta 12-PGJ2 was tested, CHM exhibited a similar rescue effect. Puromycin, mitomycin C, and alpha-amanitin did not affect PGD2 or delta 12-PGJ2 cytotoxicity. Emetine showed a variable and no consistent rescue effect CHM may have been active at the primary site where PGD2 or delta 12-PGJ2 exerts its cytotoxicity. This is the first report indicating that CHM reduces the cytotoxicity induced by PGD2 or delta 12-PGJ2.

Amanitins↗